Efficacy and safety of 25 Gy irradiated apheresis platelets in patients with hematological diseases: a meta-analysis
10.13303/j.cjbt.issn.1004-549x.2026.10.019
- VernacularTitle:25 Gy辐照单采血小板对血液病患者有效性与安全性的Meta分析
- Author:
Min GAO
1
;
Wenchao ZHAO
1
;
Yufeng SUN
1
;
Fang WANG
1
;
Ning CHENG
1
;
Li ZHAO
1
;
Wenhua WANG
1
Author Information
1. Department of Quality Management, Inner Mongolia Autonomous Region Blood Center, Hohhot 010070, China
- Publication Type:Journal Article
- Keywords:
hematological diseases;
platelet transfusion;
irradiation;
meta-analysis;
efficacy;
safety
- From:
Chinese Journal of Blood Transfusion
2026;39(10):1460-1468
- CountryChina
- Language:Chinese
-
Abstract:
Objective: Patients with hematological diseases frequently require repeated platelet transfusions due to myelosuppression; however, conventional non-irradiated products are prone to causing transfusion-associated graft-versus-host disease (TA-GVHD) and immune platelet transfusion refractoriness. Whether standard-dose 25 Gy irradiation impairs platelet function or affects transfusion efficacy has long been debated. This study aimed to systematically evaluate the efficacy and safety of 25 Gy γ-ray or X-ray irradiated apheresis platelets in patients with hematological diseases, thereby providing high-level evidence for clinical transfusion practice. Methods: The China National Knowledge Infrastructure (CNKI), Wanfang Med, VIP, PubMed, and Embase databases were systematically searched from their inception to March 16, 2026. Randomized controlled trials (RCTs) and retrospective cohort studies comparing the transfusion outcomes of 25 Gy irradiated versus non-irradiated apheresis platelets were included, and subgroup analyses were performed according to leukoreduction status. Two reviewers independently conducted literature screening, data extraction, and quality assessment. The Cochrane Risk of Bias Assessment Tool (version 1.0) and the Newcastle-Ottawa Scale (NOS) were used to evaluate the quality of the included studies. Meta-analysis was performed using RevMan 5.3 and Stata 15.1 software, and the pooled relative risk (RR) with 95% confidence interval (CI) was calculated. Results: A total of 8 studies involving 33 072 platelet transfusion episodes were included, comprising 4 RCTs and 4 retrospective cohort studies. The meta-analysis revealed that, compared with nonirradiated leukoreduced apheresis platelets, the irradiated leukoreduced group showed a significantly higher 24 h transfusion efficacy rate (RR=1.12, 95% CI: 1.09-1.14, P<0.001, I
=0%). Compared with non-irradiated apheresis platelets, the irradiated group also demonstrated a significantly improved transfusion efficacy rate (RR=1.08, 95%CI: 1.03-1.13, P=0.002, I
=47%). Regarding safety, the risk of overall adverse reactions (fever and allergic reactions) in the irradiated group was reduced by 69% (RR=0.31, 95%CI: 0.13-0.75, P=0.01, I
=0%). Heterogeneity was low across all comparisons. Quantitative publication bias test was not performed due to the limited number of included studies. Conclusion: Standarddose 25 Gy irradiation does not impair, but rather significantly improves, the platelet transfusion efficacy rate while substantially reducing the risk of transfusion adverse reactions. Based on the current moderate- and low-level evidence, the "irradiation+leukoreduction" platelet transfusion strategy may be prioritized for patients with hematological diseases requiring repeated transfusions, although higher-quality studies are still needed to further validate these conclusions.